cbdMD Moves to Acquire Twinlab

CHARLOTTE – cbdMD, Inc. entered into a definitive asset purchase agreement to acquire the operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife and Alvita Tea. The transaction is structured through an assignment for the benefit of creditors proceeding and remains subject to court approval along with customary closing conditions.

Based on unaudited figures, the combined businesses generated roughly $30 million in trailing twelve-month revenue through June 2026. That total would represent an increase of about 40% compared with cbdMD’s standalone revenue for the same period. The company said the added revenue is expected to contribute positively after transaction and integration costs. It also noted the move should lower its concentration in hemp-derived products.

Twinlab, founded in 1968, has long sold vitamins, minerals, sports nutrition and active lifestyle products through roughly 50,000 retail outlets, including The Vitamin Shoppe and GNC, as well as a notable presence on Amazon. Reserveage focuses on longevity, resveratrol, collagen and beauty-from-within offerings. Metabolife carries recognition in weight management. The brands also include performance nutrition items.

Consideration under the agreement includes the assumption of approximately $1.75 million in secured debt and the issuance of about 2.23 million shares of cbdMD common stock, representing roughly 19.9% of shares outstanding at signing. The stock portion is subject to leak-out restrictions. None of the consideration is directed to Twinlab Consolidated Holdings equity holders.

cbdMD CEO Ronan Kennedy described Twinlab as the kind of brand equity that takes decades to build and said the brands, distribution channels and team complement existing operations. Twinlab CEO Anthony Zolezzi stated that cbdMD provides a suitable home for the portfolio and that the combination would create a broader wellness offering spanning vitamins, botanicals, beauty, longevity, functional mushrooms and cannabinoids.

The agreement follows cbdMD’s earlier acquisition of Bluebird Botanicals and fits its stated approach of assembling a multi-brand platform that can share infrastructure and commerce capabilities.

Wrapping up, the transaction illustrates one path for hemp and CBD companies seeking scale and diversification through legacy supplement assets. The assignment structure and equity component reflect the financial condition of the seller while giving cbdMD access to established retail relationships. Substantial integration and court approval will determine how quickly the combined revenue base materializes and how effectively the company balances its cannabinoid and conventional wellness lines.